Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic headwinds. A key catalyst was last week’s announcement from rival Eli Lilly LLY, which reported first phase III success for its oral GLP-1 candidate,

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.